Week In Review: Biosense Exercises $75 Million Option For China Rights To Neovacs' Lupus Immunotherapy
October 13, 2018 at 17:59 PM EDT
Biosense Global, a New Jersey-Suzhou in-licensing company, exercised a $75 million option for China rights to an active lupus immunotherapy developed by Neovacs, following a successful Phase II trial of the therapeutic vaccine, IFNalpha Kinoid.
